Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC

Summary

In this study, investigators aimed to evaluated the efficacy and safety of microwave ablation combined with anlotinib and TQB2450 Solution in patients with advanced hepatocellular carcinoma. Patients were randomly assigned at a one-to-one ratio to receive microwave ablation plus anlotinib and TQB2450 Solution or microwave ablation plus TQB2450 Solution. Primary end points were objective response rate(ORR). Second end points include overall survival, progression-free survival and disease control rate. Safety was assessed in all patients.

Timeline

Start

2021-03-05

Primary completion

2022-12-31

Completion

2023-12-31

Drugs

Indications